BIIB vs REGN
BIIB and REGN side by side — valuation & fundamentals (public data).
Key statistics
| Metric | BIIBBIOGEN INC. | REGNREGENERON PHARMACEUTICALS, INC. |
|---|---|---|
| Market cap | $30.71B | — |
| P/E (TTM) | 22.4 | 19.4 |
| P/B | 2.08 | — |
| P/S | 3.1x | — |
| Revenue | $9.94B(TTM) | $15.53B(TTM) |
| Revenue growth (YoY) | 2.2% | 1.0% |
| Net income | $1.37B(TTM) | $4.33B(TTM) |
| Earnings growth (YoY) | -20.8% | 2.1% |
| EPS, diluted | $9.30(TTM) | $40.41(TTM) |
| EBIT margin | 28.7% | 24.9% |
| ROE | 8.7% | 14.2% |
| ROIC | 13.0% | 9.4% |
| Piotroski F | 4/9 | — |
| 1y total return | +62.8% | +40.0% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: BIIB vs REGN
| Metric | BIIB | REGN |
|---|---|---|
| End value | $7.4K | $18.5K |
| Total return | -25.6% | +85.1% |
| CAGR | -2.8% | +6.1% |
| Volatility | 41.3% | 32.2% |
| Sharpe | 0.03 | 0.23 |
| Sortino | 0.06 | 0.33 |
| Max drawdown | -72.7% | -59.7% |
Based on 2600 common trading days, 2016-04-06 → 2026-08-07 · risk-free 3.87% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)